Drugs / Autologous regulatory T Cell Product
last change Jan 2018 re-read 2 minutes ago

Autologous regulatory T Cell Product

Cell therapy

Developed for
end stage renal failure · liver failure
Investigated by
Guy's and St Thomas' NHS Foundation Trust · King's College London

Trials 2 · a red edge is where a trial was stopped

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT02166177 Jun 2014 → Jan 2018 liver failure Guy's and St Thomas' NHS Foundation Trust Completed No outcome recorded
Phase 1/2 NCT02129881 Apr 2014 → Mar 2017 end stage renal failure Guy's and St Thomas' NHS Foundation Trust Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Autologous regulatory T cell product ClinicalTrials.gov intervention name — accepted as the source's own label NCT02166177
1

NCT02129881

Modality Cell therapy “regulatory cell therapyNCT02166177
Route Intravenous “infused intravenously 5 days post renal transplantation” NCT02129881